It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Breast cancer is the most common type of cancer worldwide. However, the well-known molecular biomarkers are not enough to meet the needs of precision medicine. In search for novel targets in this regard, we reported ITSN1 (intersectin1) as one of the candidates through mRNA microarray analysis. In the present study, we reported that endocytic protein ITSN1-S exists not only in the cytoplasm but also in nuclei of breast cancer cells. ITSN1-S′ functional nuclear localization signal is within its residues 306–312. Its nuclear export signal (NES) resides within its SH3 domains. We also found, the interaction between the CC domain of nuclear ITSN1-S and the NT domain of nuclear DNA helicase II (NDH II) directly suppressed the DNA replication and nascent DNA synthesis by inhibiting the R-loops resolution in breast cancer cells. Furthermore, the interaction between the EH domains of cytoplasmic ITSN1-S and PI3KC2α inhibit cell migration and invasion by inactivating the PI3KC2α-AKT pathway. Our results were confirmed in both ITSN1 gene knockout cells and in vivo assays. Finally, our clinical data showed a potential application of the combined consideration of the cytoplasmic and nuclear ITSN1-S as an independent prognosis factor. In conclusion, our study revealed ITSN1-S′ novel positioning in the nuclei of breast cancer cells, its function in suppressing DNA replication, and its potential application in improved breast cancer prognosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Department of Tumor Cell Biology, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Tianjin Medical University Cancer Institute and Hospital, Tianjin’s Clinical Research Center for Cancer, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Tianjin Medical University, Ministry of Education, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
2 University of Georgia, Department of Epidemiology and Biostatistics, Institute of Bioinformatics, Athens, USA (GRID:grid.213876.9) (ISNI:0000 0004 1936 738X)
3 Tianjin Medical University Cancer Institute and Hospital, Tianjin’s Clinical Research Center for Cancer, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Key Laboratory of Cancer Prevention and Therapy, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427); Tianjin Medical University, Ministry of Education, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University Cancer Institute and Hospital, Department of Breast Cancer Pathology and Research Laboratory, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427)